Projects per year
Sharon is the Head of the new provisional Centre for Research in Mechanisms of Disease and Drug Design, in the School of Life and Medical Sciences. The Centre integrates the university's scientific expertise in the understanding of health and disease, and the design of new therapeutic strategies.
Sharon is a synthetic and medicinal chemist, with extensive research experience in the development of novel small molecules applied to understanding and treating disease.
Sharon obtained her PhD in the synthesis of natural product analogues to treat parasitic diseases, followed by postdoctoral experience in the areas of cancer pro-drug design and cardiovascular mechanisms, before joining the University in 2005.
Medicinal and biological chemistry, drug design and synthesis. Cancer drug targets and drug design. Antiobiotic-restoring peptides to combat antimicrobial resistance. Natural product analogues with anti-inflammatory properties. Small molecule cardiovascular system probes. Novel synthetic technologies.
Organic and medicinal chemistry. Integration of science and clinical aspects of pharmacy; relating structure and functions of medicines to their clinical use.
Chemistry, BSc, King's College London
PhD, Synthesis of quinolines with anthelmintic activity, King's College London
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Dive into details
Select a country/territory to view shared publications and projects
- 8 Finished
Ligand-protein studies for development of inhibitors of S100P, as a potential novel therapy for pancreatic cancer
1/04/18 → 31/12/19
1/01/18 → 31/12/19
3/03/14 → 31/07/18
1/01/13 → 31/12/16
Computational studies and synthesis of potential inhibitors of S100P, a protein implicated in pancreatic cancer
1/10/11 → 31/12/12
Rossiter, S. & Ostovar, M., 2022, Comprehensive Heterocyclic Chemistry IV. Elsevier, Vol. 10. p. 796-855
Research output: Chapter in Book/Report/Conference proceeding › ChapterOpen AccessFile14 Downloads (Pure)
Synthesis and in silico modelling of the potential dual mechanistic activity of small cationic peptides potentiating the antibiotic novobiocin against susceptible and multi-drug resistant Escherichia coliPassarini, I., Ernesto de Resende, P., Soares, S., Tahmasi, T., Stapleton, P., Malkinson, J., Zloh, M. & Rossiter, S., 30 Nov 2020, In: International Journal of Molecular Sciences. 21, 23, p. 1-19 19 p., 9134.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile1 Citation (Scopus)19 Downloads (Pure)
Discovery of novel small molecule inhibitors of S100P, with in vitro anti-metastatic effects on pancreatic cancer cellsCamara, R., Ogbeni, D., Gerstmann, L., Ostovar, M., Hurer, E., Scott, M., Mahmoud, N., Radon, T., Crnogorac-Jurcevic, T., Patel, P., Mackenzie, L. S., Chau, D., Kirton, S. & Rossiter, S., 1 Oct 2020, In: European Journal of Medicinal Chemistry. 203, 112621.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile2 Citations (Scopus)46 Downloads (Pure)
Passarini, I., Rossiter, S., Malkinson, J. & Zloh, M., 21 Jun 2018, In: Pharmaceutics. 10, 3, 72.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile8 Citations (Scopus)79 Downloads (Pure)
Anti-Inflammatory Activity of Novel Trans-Stilbene Sulfonamide Analogues as Potential Novel Therapeutic Agents for Lung DiseaseMahendran, R., Osoba, E., Rossiter, S., Bassin, J., Cook, M. & Hutter, V., 1 Aug 2017, In: Journal of Aerosol Medicine and Pulmonary Drug Delivery. 29, 3, p. A21 65.
Research output: Contribution to journal › Meeting abstract › peer-reviewOpen Access1 Citation (Scopus)